Ultragenyx Pharmaceutical (RARE) Return on Invested Capital (2018 - 2026)

Ultragenyx Pharmaceutical (RARE) has 9 years of Return on Invested Capital data on file, last reported at 0.04% in Q1 2026.

• Return on Invested Capital for Q1 2026 came in at 0.04%, up 6.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.04% (up 6.0% YoY), and the FY2025 annual result was 0.06%, down 3.0% from the prior year.
• Return on Invested Capital retreated to 0.04% in Q1 2026 per RARE's latest filing, from 0.15% in the prior quarter.
• Over five years, Return on Invested Capital peaked at 0.15% in Q4 2025 and troughed at 0.09% in Q3 2025.
• A 5-year average of 0.02% and a median of 0.02% in 2025 frame the typical range for Return on Invested Capital.
• On a YoY basis, Return on Invested Capital climbed as much as 18 bps in 2025 and fell as far as 8 bps in 2025.
• A 5-year view of Return on Invested Capital shows it stood at 0.02% in 2022, then sank by 131 bps to 0.04% in 2023, then gained by 16 bps to 0.03% in 2024, then jumped by 588 bps to 0.15% in 2025, then sank by 77 bps to 0.04% in 2026.
• Business Quant data shows RARE's Return on Invested Capital at 0.04% in Q1 2026, 0.15% in Q4 2025, and 0.09% in Q3 2025.